Guselkumab is prescribed for:
- Moderate-to-severe plaque psoriasis
- Psoriatic arthritis
- Dermatologic autoimmune conditions
Targets IL-23, a cytokine upstream in the inflammatory cascade.
Generic Name: Guselkumab
Brand Names: Tremfya
Guselkumab is an IL-23 inhibitor biologic for moderate-to-severe plaque psoriasis and psoriatic arthritis.
Guselkumab is prescribed for:
Targets IL-23, a cytokine upstream in the inflammatory cascade.
Common side effects:
Serious side effects:
Guselkumab is a monoclonal antibody targeting the p19 subunit of IL-23.
By blocking IL-23 (which stimulates Th17 cells to produce IL-17), guselkumab may provide more sustained disease control.
After loading doses, maintenance is every 8 weeks, offering convenience.
For details, see MedlinePlus.
This medication is commonly used to treat or manage the following conditions:
Coronary Artery Disease (CAD) results from plaque buildup in coronary arteries (atherosclerosis), restricting blood flow and potentially causing angina, heart attack, or heart failure, influenced by factors like high blood pressure and cholesterol.
Heart failure stemming from coronary artery disease arises from narrowed arteries restricting blood flow, weakening or stiffening the heart muscle and reducing its pumping efficiency.
Osteoarthritis, a common degenerative joint disease, causes pain, stiffness, and reduced motion due to cartilage breakdown from aging, genetics, obesity, injuries, or repetitive stress.
Medical Disclaimer: This information is for educational purposes only and should not be considered medical advice. Always consult with your healthcare provider before starting, stopping, or changing any medication. Your doctor can provide personalized recommendations based on your specific health condition and medical history.
Loading questions...
Have questions about Guselkumab? Get expert answers from Dr. Zimmer.
Privacy: Your questions are posted anonymously for your health privacy. Your name and email are only used for admin purposes.
Questions are reviewed before posting. You'll see your question and Dr. Zimmer's answer below once approved.